A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration

International Journal of Artificial Organs

Volumn 30, Issue 4, 2007, Pages 301-307

  Fealy, N ^a   Baldwin, I ^a   Johnstone, M ^b   Egi, M ^a   Bellomo, Rinaldo ^a,c  

^a AUSTIN HOSPITAL   (Australia)

^b RMIT UNIVERSITY   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

Acute renal failure; Anticoagulation; Citrate; Continuous renal replacement therapy; Continuous venovenous hemofiltration; Heparin

Indexed keywords

ACUTE RENAL FAILURE; ANTI-COAGULATION; CITRATE; CITRATE METHODS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTINUOUS VENOVENOUS HEMOFILTRATION; HEMOFILTRATION; HEPARINIZATION; RENAL FAILURE; RENAL REPLACEMENT THERAPIES;

POLYSACCHARIDES;

CALCIUM; CITRIC ACID; HEPARIN; PROTAMINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTICOAGULANT THERAPY; APACHE; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; FEMALE; HEPARINIZATION; HUMAN; INTENSIVE CARE UNIT; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 34250615521     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000404     Document Type: Article

References (31)

1. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous is not continuous: The incidence and impact of circuit down time on uremic control during continuous venovenous haemofiltration. Intensive Care Med 2003; 29:575-8.
2. Fealy N, Baldwin I, Bellomo R. The effect of circuit "down time" on uraemic control during continuous veno-venous haemofiltration. Crit Care Resusc 2002; 4:266-70.
3. Baldwin I, Bridge N, Elderkin T. Nursing Issues, practices, and perspectives for the management of continuous renal replacement therapy in the intensive care unit. Crit Care Nephrol 1998; 1309-25.
4. Holt AW, Bierer P, Bersten AD, Bury LK, Vedig AE. Continuous renal replacement therapy in critically ill patients: Monitoring circuit function. Anaesth Intensive Care 1996; 24: 423-9.
5. Baldwin I, Elderkin T. Continuous hemofiltration: Nursing perspectives in critical care. New Horizons 1995; 3: 738-47.
6. Van de Wetering J, Westendrop RG, Hoeven JG, Van der Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145-50.
7. Reeves J, Cumming A, Gallagher L, O'Brien J, Sanatamaria J. A controlled trial of low molecular weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27: 2224-8.
8. Fiaccadori E, Maggiore U, Rotelli C. Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med 2002; 28:586-93.
9. Ohtake T, Hirasawa H, Sugai T. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991; 93: 215-7.
10. Favre H, Martin P, Stoermann C. Anticoagulation in continuous extracorporeal renal replacement therapy. Semin Dial 1996; 9: 112-8.
11. Prasad GV. Factors affecting system clotting in continuous renal replacement therapy: Results of a randomised, controlled trial. Clin Nephrol 2000; 53: 55-60.
12. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Predilution vs. post-dilution during continuous veno-venous hemofiltration: Impact on filter life and azotemic control. Nephron 2003; 94:94-8.
13. Van der Voort P, Gerritsen R, Kuiper M, Egbers P, Kingma W, Boerma E. Filter run time in CVVH: Pre versus post dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 2005; 23: 175-80.
14. Tan H, Baldwin I, Bellomo R. Continuous venovenous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26:1652-7.
15. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 1997; 30: s20-7.
16. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: Anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003; 16: 566-71.
17. Stefanidis I, Hagel J, Maurin N. Influence of coagulation parameters on filter running time during continuous venovenous hemofiltration. Contrib Nephrol 1995; 116:145-9.
18. Biancofiore G, Esposito M, Bindi L, et al. Regional filter heparinization for continuous venovenous hemofiltration in liver transplant recipients. Minerva Anesthesiology 2003; 69: 527-34.
19. Samuelsson O, Amiral J, Attman P. Heparin-induced thrombocytopaenia during continuous renal replacement therapy. Nephrol Dial Transplant 1995; 10:1768-71.
20. Carr J, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg 1999; 40:659-66.
21. Mehta R, McDonald B, Aguilar M, Ward D. Regional citrate anticoagulation in continuous arteriovenous hemodilaysis in critically ill patients. Kidney Int 1990; 38: 976-81.
22. Thoenen M, Schmid E, Binswanger U, Schuepbach R, Aerne D, Schmidlin D. Regional citrate anticoagulation using citrate based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients. Klin Wochenchrift 2002; 114: 108-14.
23. Hoffman M, Maloney C, Ward D, Becker B. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Ren Fail 2002; 24: 325-35.
24. Gabutti L, Marone C, Giuseppe C, Francesca D, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: A metabolic challenge. Intensive Care Med 2002; 28:1419-25.
25. Tobe S, Aujla P, Walele A, et al. A novel regional citrate anticoagulation protocol for CRRT using commercially available solutions. J Crit Care 2003; 18:121-9.
26. Mitchell A, Daul A, Beiderlinden M, et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol 2003; 59:106-14.
27. Monchi M, Berghmans D, Ledoux D, Canivet J, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomised study. Intensive Care Med 2005; 30: 260-5.
28. Kutsogiannis D, Gibney R, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-7.
29. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, and the ADQI workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the ADQI Group. Critical Care 2004; 8: R204-12.
30. Bellomo R, Teede H, Boyce N. Anticoagulation regimens in acute continuous hemodiafiltration. Intensive Care Med 1993; 19: 329-32.
31. Egi M, Naka T, Bellomo R, et al. A comparison of two citrate anticoagulation regimens for continuous venvenous hemofiltration. Artificial Kidney and Dialysis 2005; 28: 1211-8.